ESC 365 - Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, the AFLOAT randomized study

ESC Professional Premium Access

Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, the AFLOAT randomized study

Session: Smaller trials, trial updates, and other studies on atrial fibrillation

Topic: Patent Foramen Ovale (PFO) / Atrial Septal Defect (ASD) Closure

Speaker: Professor G. Montalescot (Paris, FR)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Professor Gilles Montalescot

Pitie Salpetriere APHP University Hospital, Paris (France)

35 presentations

1 follower

4 more presentations in this session

Enhanced Detection and Quickened Diagnosis of Atrial Fibrillation Using Apple Watch: A Randomized Controlled Trial

Speaker: Doctor M. Winter (Amsterdam, NL)

Detection of silent atrial fibrillation in high stroke risk patients using bed sensor and smartphone app: the CARE-DETECT trial

Speaker: Doctor J. Lehto (Turku, FI)

Atrial fibrillation follow-up investigation to recover memory and learning trial

Speaker: Doctor X. Du (Beijing, CN)

Manual chest PRESSURE during direct current cardioversion for Atrial Fibrillation: a randomized control trial (PRESSURE-AF).

Speaker: Doctor D. Ferreira (Newcastle, AU)

Access the full session

Smaller trials, trial updates, and other studies on atrial fibrillation

Speakers: Professor G. Montalescot, Doctor M. Winter, Doctor J. Lehto, Doctor X. Du, Doctor D. Ferreira

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources